Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Phase 2

Conditions: Lymphoma, Non-Hodgkin
Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ondansetron
Drug: Dexamethasone
Drug: Diphenhydramine
Drug: Acetaminophen
Other: PET Scan
Drug: Ifosfamide
Drug: Mesna (IV)
Drug: Mesna (oral)
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab

First Posted Date: 2006-05-11

Last Posted Date: 2021-07-22

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 150

Registration Number: NCT00324467

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Phase 3

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Myelodysplastic Syndrome With Isolated Del(5q)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Previously Treated Myelodysplastic Syndromes
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Radiation: total-body irradiation
Procedure: allogeneic hematopoietic stem cell transplantation
Drug: mycophenolate mofetil
Drug: cyclophosphamide
Drug: cyclosporine
Drug: busulfan
Drug: fludarabine phosphate
Procedure: peripheral blood stem cell transplantation
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis
Genetic: cytogenetic analysis
Other: flow cytometry
Other: pharmacological study
Genetic: fluorescence in situ hybridization
Drug: tacrolimus
Genetic: polymorphism analysis
Drug: methotrexate

First Posted Date: 2006-05-04

Last Posted Date: 2014-10-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00322101

Locations: 🇺🇸
Weill Cornell University, New York, New York, United States
🇺🇸
HealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Emory University, Altanta, Georgia, United States

and more 5 locations

Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia

Phase 1

Completed

Conditions: Fanconi Anemia

First Posted Date: 2006-04-25

Last Posted Date: 2012-04-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 25

Registration Number: NCT00317876

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇧🇷
Universidade Federal do Parana, Curitiba, Parana, Brazil
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Phase 2

Completed

Conditions: Leukemia
Lymphoma
Myelodysplastic Syndromes

First Posted Date: 2006-04-25

Last Posted Date: 2010-05-07

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00317785

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Acute Myelogenous Leukemia
Relapsed Leukemia

Interventions: Drug: clofarabine
Drug: Etoposide
Drug: Cyclophosphamide

First Posted Date: 2006-04-19

Last Posted Date: 2014-04-14

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 50

Registration Number: NCT00315705

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 10 locations

Sequential vs Upfront Intensified Neoadjuvant Chemotherapy in Patients With Large Resectable or Locally Advanced Breast Cancer.

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Docetaxel

First Posted Date: 2006-04-17

Last Posted Date: 2010-03-18

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 200

Registration Number: NCT00314977

Locations: 🇳🇱
Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands
🇳🇱
Deventer Ziekenhuis, Deventer, Netherlands
🇳🇱
Catharina Ziekenhuis, Eindhoven, Netherlands

and more 21 locations

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Biological: Melanoma Reactive TIL
Drug: Cyclophosphamide
Biological: IL-2
Drug: Fludarabine
Radiation: 1200 total body irradiation (TBI)

First Posted Date: 2006-04-12

Last Posted Date: 2012-10-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00314106

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2006-04-06

Last Posted Date: 2013-06-26

Lead Sponsor: Gruppo Italiano Mammella (GIM)

Target Recruit Count: 280

Registration Number: NCT00311636

Locations: 🇮🇹
Ospedale Civile, Castelfranco - TV, Italy
🇮🇹
Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
🇮🇹
Ospedale Sant Anna, Como, Italy

and more 15 locations

Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer

Not Applicable

Conditions: Breast Cancer

First Posted Date: 2006-04-03

Last Posted Date: 2009-02-09

Lead Sponsor: Heinrich-Heine University, Duesseldorf

Target Recruit Count: 1234

Registration Number: NCT00309920

Locations: 🇩🇪
Knappschaft Krankenhaus, Bochum-Langendreer, Germany
🇩🇪
Praxis Fuer Haematologie Internistische Onkologie, Cologne, Germany
🇩🇪
St. Elisabeth-Krankenhaus - Koeln, Cologne, Germany

and more 44 locations

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

Phase 2

Completed

Conditions: Acute Lymphocytic Leukemia
MDS
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Lymphoma
Refractory Anemia
Myelodysplastic Syndromes
Chronic Myelogenous Leukemia
Myelofibrosis
Prolymphocytic Leukemia

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cyclosporine
Drug: fludarabine phosphate
Drug: mycophenolate mofetil
Procedure: umbilical cord blood transplantation
Radiation: total-body irradiation

First Posted Date: 2006-04-03

Last Posted Date: 2020-09-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 213

Registration Number: NCT00309842

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy